AAV Gene Therapy for the Treatment of Autosomal Dominant Alzheimer’s Disease

Time: 10:00 am
day: Day Two


  • The role of presenilin in ADAD and rationale for a gene replacement approach
  • Preclinical proof-of-principle data in mouse models and human-derived ADAD mutation-bearing cell lines
  • Evaluating expression and biodistribution in nonhuman primates
  • Discussing phase 1/2 clinical trial plans